Diffuse large B cell lymphoma: Using pathologic and molecular biomarkers to define subgroups for novel therapy

Antonino Carbone, Annunziata Gloghini, Yok Lam Kwong, Anas Younes

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.

Original languageEnglish
Pages (from-to)1263-1277
Number of pages15
JournalAnnals of Hematology
Volume93
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Biomarkers
B-Lymphocytes
Mutation
Germinal Center
Gene Expression Profiling
Therapeutics
Lymphoma
Cell Survival
Immunohistochemistry
Clinical Trials
Technology
Growth
Neoplasms

Keywords

  • Biomarkers
  • Diagnosis
  • DLBCL
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Diffuse large B cell lymphoma : Using pathologic and molecular biomarkers to define subgroups for novel therapy. / Carbone, Antonino; Gloghini, Annunziata; Kwong, Yok Lam; Younes, Anas.

In: Annals of Hematology, Vol. 93, No. 8, 2014, p. 1263-1277.

Research output: Contribution to journalArticle

@article{1f1dce252b654b659e20e05875119ea3,
title = "Diffuse large B cell lymphoma: Using pathologic and molecular biomarkers to define subgroups for novel therapy",
abstract = "Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the {"}activated B cell{"} subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The {"}germinal center B cell-like{"} subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.",
keywords = "Biomarkers, Diagnosis, DLBCL, Prognosis, Treatment",
author = "Antonino Carbone and Annunziata Gloghini and Kwong, {Yok Lam} and Anas Younes",
year = "2014",
doi = "10.1007/s00277-014-2116-y",
language = "English",
volume = "93",
pages = "1263--1277",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Diffuse large B cell lymphoma

T2 - Using pathologic and molecular biomarkers to define subgroups for novel therapy

AU - Carbone, Antonino

AU - Gloghini, Annunziata

AU - Kwong, Yok Lam

AU - Younes, Anas

PY - 2014

Y1 - 2014

N2 - Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.

AB - Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.

KW - Biomarkers

KW - Diagnosis

KW - DLBCL

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84904743618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904743618&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2116-y

DO - 10.1007/s00277-014-2116-y

M3 - Article

C2 - 24870942

AN - SCOPUS:84904743618

VL - 93

SP - 1263

EP - 1277

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -